You are now leaving Abacavir HSR Support. ViiV/GSK do not recommend, endorse or accept liability for sites controlled by third parties.
Clinical diagnosis of suspected hypersensitivity to abacavir remains the basis for clinical decision making
- HLA-B*5701 screening for risk of abacavir hypersensitivity should never be substituted for appropriate clinical vigilance and patient management in individuals receiving abacavir
- HLA-B*5701 testing must not be used as a diagnostic test after a patient has started treatment with abacavir